Document is current
Any future updates will be listed below
-
Authors
Feldman, Steven R.
Gao, Ran
Bohn, Rhonda L.
Gray, Stephani
Déruaz-Luyet, Anouk
Wu, Jashin J. https://orcid.org/0000-0002-1722-1892
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim
- License Information
-
More Information
Article History
Received: 5 December 2024
Accepted: 20 January 2025
First Online: 3 March 2025
Declarations
:
: Steven R. Feldman declares receiving research, speaking, and/or consulting support from AbbVie, Accordant, Advance Medical, Almirall, Alvotech, Amgen, Arcutis, Arena Pharmaceuticals, Argenx, Biocon, Boehringer Ingelheim, Bristol Myers Squibb, Caremark, Celgene, Dermavant, Eli Lilly, Galderma, GSK/Stiefel, Helsinn, Informa, Janssen, Leo Pharma, Menlo, Merck, Mylan, National Biological Corporation, National Psoriasis Foundation, Novan, Novartis, Pfizer, Qurient, Regeneron, Samsung, Sanofi, Sun Pharmaceutical Industries, Suncare Research Laboratories, UCB, UpToDate, Valeant, and vTv Therapeutics. He is also the founder and majority owner of and has stock in Sensal. Ran Gao is a former employee of Boehringer Ingelheim. Rhonda L. Bohn is the founder of Bohn Epidemiology, LLC, and has served as a consultant to Boehringer Ingelheim. Stephani Gray declares being a consultant to Boehringer Ingelheim and Bohn Epidemiology, LLC. Anouk Déruaz-Luyet is an employee of Boehringer Ingelheim. Jashin J. Wu declares being an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Aristea Therapeutics, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, DermTech, Dr. Reddy’s Laboratories, Eli Lilly, EPI Health, Galderma, Janssen, Leo Pharma, Mindera, Novartis, Pfizer, Regeneron, Samsung Bioepis, Sanofi Genzyme, Solius, Sun Pharmaceutical Industries, UCB, and Zerigo Health.
: The MarketScan and Optum databases contain commercially and non-commercially insured populations in the USA. All patient data were anonymized; therefore, informed consent was not necessary. Institutional review board approval is not required for publications citing Optum data. Optum data only contains de-identified health information as described by the HIPPA Privacy Rule. No direct identifiers of individuals, employers, households, or providers are included; as such, the study is exempt from patient consent requirements.
